Race Oncology Initiates $8.6M Phase 1 Trial for RC220 in Solid Tumors

The latest announcement is out from Race Oncology Ltd. ( (AU:RAC) ).

Race Oncology Ltd has executed an $8.6 million contract with George Clinical International to support a Phase 1 trial of RC220 bisantrene in combination with doxorubicin for patients with advanced tumors in Australia, Hong Kong, and South Korea. This trial aims to assess the safety, pharmacokinetics, and maximum tolerated dose of the combination, with initial data on its cardioprotective and anticancer effects. The trial’s success could enhance Race’s positioning in the oncology market by offering a novel treatment that mitigates heart damage from anthracyclines while improving cancer treatment.

More about Race Oncology Ltd.

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, bisantrene, is a small molecule chemotherapeutic known for its anticancer effects and reduced cardiotoxicity compared to certain anthracyclines. The company is advancing a reformulated version, RC220, to address unmet needs in oncology, particularly in anthracycline combinations for solid tumors, and is exploring its potential in acute myeloid leukemia.

YTD Price Performance: -15.56%

Average Trading Volume: 67,081

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$198M

For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.